SpyGlass Pharma, Inc. SGP

Updated: 19 Jun 2026

NASDAQ | Biotech | Ophthalmic drug delivery systems

No signal published yet

We already track SpyGlass Pharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow SpyGlass Pharma free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Ophthalmic drug delivery systems
We're already tracking SpyGlass Pharma, Inc. — here are the latest events we've registered

Recent News

  • In June 2026, the company appointed Shannon Treviño as General Counsel and Mike Pinder as Vice President of Marketing to strengthen its leadership team. Earlier in 2026, SpyGlass reported positive 12-month Phase 1/2 results for its BIM-IOL System, which demonstrated sustained intraocular pressure control. The company is currently advancing two registrational Phase 3 trials for the system.

What Firelda Watch includes for SpyGlass Pharma, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of SpyGlass Pharma, Inc. will be delivered in the same format.

Want to follow SpyGlass Pharma, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow SpyGlass Pharma free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

SpyGlass Pharma, Inc. SGP
SpyGlass Pharma — follow and we'll monitor it
Follow SpyGlass Pharma free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.